RxDoctor Payments Data

Charles Browning

Family · Shelby, NCNPI 1295302024

Payments from drug & device makers

$1,004in general payments, 2019–2025

Across 68 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$322
  • Boehringer Ingelheim$173
  • Novo Nordisk$153
  • AstraZeneca$71
  • Lilly USA, LLC$69
  • Bayer$53
  • plus $164 from 6 others

What the payments were for

  • Food & beverage$1,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,004 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,390
Medicare patients
58
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$42,070
OzempicSemaglutide26$31,900
FarxigaDapagliflozin Propanediol28$30,781
EliquisApixaban33$27,604
JanuviaSitagliptin Phosphate14$18,712
XareltoRivaroxaban12$16,908
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,990
SymbicortBudesonide/Formoterol Fumarate28$9,022
MyrbetriqMirabegron16$8,044
Albuterol Sulfate HfaAlbuterol Sulfate128$3,725
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,154
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,824
Gabapentin131$2,802
Omeprazole176$2,640
Atorvastatin Calcium321$2,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$173$42,07038 claims
AstraZenecaFarxiga, Symbicort$71$39,80456 claims
Novo NordiskOzempic$153$31,90026 claims
PfizerEliquis$13$27,60433 claims
GSKTrelegy Ellipta$21$12,99019 claims
AbbVieSynthroid$322$1,93317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Shelby

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →